|Bid||102.36 x 900|
|Ask||102.74 x 800|
|Day's Range||101.82 - 103.84|
|52 Week Range||43.29 - 105.50|
|Beta (5Y Monthly)||0.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||102.57|
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on October 1, 2020, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 77,118 shares of its common stock and an aggregate of 38,557 restricted stock units (RSUs) to five new employees, including a grant of non-qualified stock options to purchase 65,000 shares of common stock and 32,500 RSUs to Fouad Namouni, M.D., the company's recently appointed President, Research & Development , under Blueprint Medicines' 2020 Inducement Plan.
Buying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly...
Blueprint Medicines' (BPMC) lead drug Ayvakyt/Ayvakit approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's efforts to expand the drug's label are promising as well.